Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF, a New Plateau -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (1305)	7/26/2002 1:13:15 PM
From: JOEBT1	Read Replies (1) \| Respond to of 2243

Richard-I'm still around in biotechs somewhat bruised and battered but still smiling-could have been a lot worse. As usual I want to tap your wisdom. I'm looking at Aphton (APHT), bought a little but not comfortable with the company. Somewhat like Genta but without Paramount Capital-sort of a virtual company. They got fantastic results with G17DT in a PII stomach cancer trial--36 patients,1 CR, 18 PR and 11 stable disease for an 83% overall response. They got a blue ribbon for an ASCO presentation on the drug. They just received orphan drug status for two applications of G17DT, pancreatic cancer (in PIII) and stomach cancer (going into PIII but hoping that the FDA will accept their PII results for approval). They have enough money for this year ( 23M at 3/31 but burning at 8 to 9M rate per quarter). They have a 5 million share shelf registration and are selling at $4.10. They have 2 major pharma partners (Aventis and SKB) but don't seem to get financial help from them on the trials. Their financial structure seems to be clean with 20M shares outstanding. I think they been working for years with this drug. If you're still reading this, thank you ;-), I would appreciate anything you can offer on this company. (You might want it for your portfolio :-)). Joe